Chelsea Counsel Company’s Citius Pharmaceuticals CTXR Stock Holding History

Chelsea Counsel Company’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.16K	Hold	4,626	–	–	﹤0.01%	192
2025 Q4	$3.6K	Hold	4,626	–	–	﹤0.01%	196
2025 Q3	$5.74K	Hold	4,626	–	–	﹤0.01%	187
2025 Q2	$7.36K	Hold	4,626	–	–	﹤0.01%	182
2025 Q1	$6.89K	Buy	+4,626	New	+$11.1K	﹤0.01%	177
2024 Q4	–	Sell	-11,252	Closed	-$141K	–	199
2024 Q3	$141K	Buy	11,252 +1,000	+10%	+$16.8K	0.07%	108
2024 Q2	$150K	Buy	10,252 +7,000	+215%	+$125K	0.07%	104
2024 Q1	$73K	Hold	3,252	–	–	0.04%	105
2023 Q4	$61.5K	Hold	3,252	–	–	0.03%	113
2023 Q3	$55.6K	Hold	3,252	–	–	0.03%	122
2023 Q2	$97.6K	Hold	3,252	–	–	0.05%	114
2023 Q1	$95.1K	Buy	+3,252	New	+$93.7K	0.05%	114

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Chelsea Counsel Company's CTXR Position: Q1 2026 in Review

Chelsea Counsel Company held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 4,626 shares worth $4.16K. The position accounts for ﹤0.01% of the portfolio, ranked #192.

Chelsea Counsel Company first reported a position in CTXR in Q1 2023 and has held it in 12 quarters since. The position peaked at $150K in Q2 2024. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

Chelsea Counsel Company held 4,626 shares of Citius Pharmaceuticals worth $4.16K as of Q1 2026.
Chelsea Counsel Company left its Citius Pharmaceuticals share count unchanged in Q1 2026.
Citius Pharmaceuticals made up ﹤0.01% of Chelsea Counsel Company's portfolio in Q1 2026, its #192 holding.
Chelsea Counsel Company first reported a position in Citius Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
Chelsea Counsel Company's Citius Pharmaceuticals position peaked at $150K in Q2 2024.
38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Chelsea Counsel Company's 13F filing for Q1 2026, filed 24 Apr 2026.